Biotechnology

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

At a major oncology conference, Zephyr AI will showcase AI that predicts patient response to targeted therapies, aiming to personalize cancer treatment.

With $108M in new funding, Terremoto Biosciences advances a novel class of drugs designed to overcome the toxicities of past cancer treatments.

Following a major partnership, AST and Marchesini Group will showcase next-gen robotic filling and inspection tech, aiming to reshape sterile drug production.

With new top-tier executives, Danish biotech MinervaX is accelerating its quest to deliver the world's first vaccine against a leading cause of infant death.

OncoHost's new research shows a patient's "biological age" can predict immunotherapy success, a potential breakthrough in personalized oncology.

With a fresh $28M investment, Verismo Therapeutics is set to unveil groundbreaking KIR-CAR data, aiming to revolutionize CAR T therapy for solid tumors.

Atelerix's revolutionary hydrogel eliminates the need for cold chain logistics, partnering with JH Health to unlock the booming Saudi biotech market.

Shanghai's SinoUnited Health is attracting global patients with advanced care like CAR-T therapy at a fraction of US prices, challenging medical tourism hubs.

With backing from AI leaders, Helical’s virtual lab aims to turn powerful models into reproducible drug discovery systems, tackling a key industry bottleneck.

Win a VIP trip to meet P!NK while supporting vital cancer research. A new fundraising model emerges as public funding for life-saving science dwindles.

Phase 3 data shows GTx-104 reduces key risks and improves outcomes for aSAH patients, positioning it as a potential new standard of care ahead of an FDA decision.

MeiraGTx will present 3-year data on a one-time therapy for radiation-induced dry mouth, a condition affecting millions of head and neck cancer survivors.

Biotech firm Genvor leverages its AI platform in a new partnership, aiming to fast-track novel peptides for anti-aging and weight loss to a booming market.

With its lead depression drug nearing Phase 3, AtaiBeckley faces investors to tackle the regulatory and commercial hurdles of psychedelic medicine.

Eli Lilly acquires CrossBridge Bio for its innovative dual-payload ADC platform, signaling a major push into the next wave of targeted cancer treatments.

BioTesserae's BTC-001, a novel immunotherapy, proves safe in early trials, paving the way for more affordable and accessible treatment for dogs.

As Ontario hospitals face a financial crisis, a major innovation week aims to connect Canadian startups with global capital to solve healthcare's biggest challenges.

A new, non-invasive urine test from TOBY, Inc. has received FDA Breakthrough status, challenging blood-based rivals and promising a new era of accessible cancer detection.

Taiwanese biotech GlycoNex will begin human trials for GNX1021, a novel ADC that targets cancer's unique sugar coating to fight GI tumors.